Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$366.69 4.44 (1.22)%
Market Cap 37.91B
10/25/16 2:42 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Regeneron Pharmaceuticals Q3 2016 Earnings Conference Call
Nov 4, 2016 | 8:30 AM
25th Annual Credit Suisse Healthcare Conference
Nov 8, 2016 | 10:00 AM